Displaying drugs 14851 - 14875 of 15128 in total
CTS-21166
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and …
Dipipanone
Experimental
Illicit
2,3,4,5,6-Pentafluorobenzyl Alcohol
Experimental
N-[3-(aminomethyl)benzyl]acetamidine
Experimental
Iodobenzene
Experimental
ES-936
Experimental
AL7182
Experimental
S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
Experimental
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole
Experimental
4-Fluorophenethyl Alcohol
Experimental
1,3,5-trichlorobenzene
Experimental
1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea
Experimental
N-(Chlorophenyl)-N'-hydroxyguanidine
Experimental
(R)-4-Nitrostyrene oxide
Experimental
1-[4-(hydroxymethyl)phenyl]guanidine
Experimental
Displaying drugs 14851 - 14875 of 15128 in total